论文部分内容阅读
目的观察长春瑞滨联合顺铂治疗晚期非小细胞肺癌(NSCLC)的疗效及毒副反应。方法长春瑞滨25mg/m2,第一、五天,顺铂25mg/m2,第一～三天,第二十一天为1周期,两周期以上评价疗效。结果可评价疗效57例,其中完全缓解(CR)1例,部分缓解(PR)23例,无变化(NC)20例,疾病进展(PD)13例,总有效率CR+PR42.1%。全组中位PFS为4个月,中位生存期9个月。主要毒副反应为骨髓抑制、恶心、呕吐。结论长春瑞滨联合DDP治疗晚期非小细胞肺癌疗效高,毒副反应可耐受,可以作为治疗晚期非小细胞肺癌的一线治疗方案。
Objective To observe the efficacy and side effects of vinorelbine plus cisplatin in the treatment of advanced non-small cell lung cancer (NSCLC). Methods Vinorelbine 25mg / m2, the first and fifth days, cisplatin 25mg / m2, the first to three days, the first 21 days for a period of more than two weeks to evaluate the efficacy. Results Fifty-seven patients were evaluated for complete response (CR), partial response (PR), 23 cases of no change (NC) and 13 cases of progressive disease (PD). The total effective rate was CR + PR 42.1%. The median overall PFS was 4 months and the median survival was 9 months. The main side effects of bone marrow suppression, nausea, vomiting. Conclusions Vinorelbine combined with DDP in the treatment of advanced non-small cell lung cancer has high curative effect and tolerable side effects and can be used as a first-line treatment for advanced non-small cell lung cancer.